search

About Cell Therapies

Delivering the Promise of Cell and Gene Therapies

Cell Therapies is a commercial contract development and manufacturing organisation (CDMO) that manufactures and delivers advanced cell and gene therapies to patients across Australia and the Asia–Pacific region.

Our structure has been purpose-built to address the evolving needs of cell and gene therapy developers. Embedded within a leading biomedical precinct and co-located with the world-class Peter MacCallum Cancer Centre, we maintain close ties with clinical investigators, key opinion leaders and academic scientists, while operating independently under GMP-licensed conditions.

Our unique positioning enables us to:

  • Translate preclinical data into trial-ready manufacturing protocols
  • Respond quickly to protocol changes and investigator feedback
  • Maintain scientific continuity and programme knowledge across the development lifecycle
View Our ServicesTalk to Us
About Cell Therapies history
Over 20 years of sector Experience

Cell Therapies has over 20 Years' Sector Experience

Access Our In-depth Expertise to Drive Your Programs' Success

Since 2003, Cell Therapies has manufactured cell therapies, ex vivo gene therapies and regenerative medicine products under GMP standards, meeting global regulatory requirements.

Our expertise spans the full product development pipeline, from first-in-human studies and early- to late-phase clinical trials through to commercial supply. We have extensive experience in Quality Management Systems (QMS) and in supporting the Australian healthcare system in delivering innovative cell and gene therapies.

View Our FacilityTalk To Us

GMP Manufacturing Capability and Capacity

Clinical and Commercial Supply

Cell Therapies is Australia’s only biomedical manufacturing facility where CAR T-cells and other cell-based therapies can be produced at commercial volumes. The facility supports both autologous and allogeneic products and includes 10 GMP cleanrooms suitable for early to mid-stage clinical trial supply, and 3 large-scale high-throughput GMP manufacturing suites for late-phase clinical and commercial supply with a production capacity of up to 2,000 patient doses per year.

Our GMP manufacturing facility is co-located with the Peter MacCallum Cancer Centre in the heart of Melbourne’s Premier Biomedical Precinct, providing access to hospitals, research institutes, and universities to support product development, translation to the clinic, and patient access.

Learn More About Our FacilityBook a Tour
About our Capabilities
Inside the corridors of Cell Therapies

Contract Manufacturing to Meet Global Regulatory Standards

Regulatory Accreditations to Support Market Access

Cell Therapies’ facility and Quality Management System (QMS) meets global regulatory standards benchmarked by the Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S) and international regulatory agency requirements including those of the Australian TGA, the United States of America’s FDA, Japan’s PMDA, South Korea’s MFDS, Singapore’s HSA, and Europe’s EMA.

Cell Therapies is Australia’s only TGA-licenced GMP facility for manufacturing of both commercial and clinical trial cell therapy products, including CAR T-cell therapies, and has accreditation for supply of regenerative medicine products from Japan’s Ministry of Health, Labour and Welfare (MHLW).

Learn More About Contract ManufacturingTalk to Us

The Cell Therapies Advantage

Experienced

Over 20 years’ experience in GMP manufacturing of cell and gene therapies for clinical trials and commercial supply

Quality Control and Analytics

In-house Quality Control and analytical testing capabilities for method development and final product release

Regional Reach

Regulatory approvals and key partnerships to reliably deliver time-critical, temperature-sensitive products to patients across the Asia-Pacific region

Exceptional Quality Systems

Robust and flexible Quality Management System (QMS) with a proven track record

Clinically Integrated

Full integration into the Australian healthcare system to support clinical trials and commercial supply of cell and gene therapies to patients

Capacity and Capability

World-class facility, highly skilled personnel, digitalisation and automation, and workflows to support our clients’ goals

To reach out to our expert team and find out more about our services, get in touch and we will contact you to arrange a call at a time that suits you.

Talk to us
Our Purpose and Values

Our Purpose and Values

Driven By Excellence

At Cell Therapies our Purpose is to deliver the promise of advanced therapies.

Working every day to impact peoples’ lives, our culture is rooted in our core Values of connection, respect, curiosity and integrity.

Careers at Cell Therapies

Our Leadership Team

Dr Bev Menner

Dr Bev Menner

Chief Executive Officer

Bev has over 20 years’ experience across the Australian and global biopharmaceutical & healthcare sectors. She holds a PhD in molecular medicine with additional qualifications in genetic counselling, project management and decision analysis.

Bev commenced her career with Postdoctoral roles in cancer research at Memorial Sloan Kettering Cancer Centre and the Peter MacCallum Cancer Centre, before moving to genetic counselling practice and then commercial roles in research & development, portfolio management and strategic partnerships in the pharmaceutical industry.

Colin McLean

Colin McLean

Chief Operating Officer

Colin McLean is Chief Operating Officer at Cell Therapies Pty Ltd. With over 14 years of experience in GMP-regulated environments, Colin has led Manufacturing, Quality Control and Quality Assurance operations, cross-functional teams, and regulatory compliance efforts to support clinical and commercial programs.
He currently oversees manufacturing, supply chain, validation, and project delivery, and leads the Asia Pacific Alliance Model to improve access to advanced therapies across the region.
Colin holds a Master’s in Transfusion, Transplantation and Tissue Banking from the University of Edinburgh. His background includes regulatory audits, assay validation, tech transfer, and GMP consultancy across a wide range of ATMPs. He is committed to building strong, reliable operations that enable high-quality therapy delivery and long-term partnerships globally.
svg+xml;charset=utf

Thomas Ulmer

Chief Financial Officer

Thomas Ulmer is a senior financial executive with nearly 20 years’ experience across global biotechnology, biopharmaceutical and digital health organisations. He has led financial strategy, capital markets activity and business transformation across Australia, Europe and the United States.

Thomas began his career in senior finance and commercial roles at Merck and Mylan, before moving into executive leadership positions including Chief Financial Officer of Immatics N.V., where he co-led the company’s NASDAQ listing. Most recently, he served as CEO of PKG Health, driving the company’s commercial transformation, expanding its global partnerships, and successfully repositioning the business for growth.
svg+xml;charset=utf

Kate MacCormack

Director of Human Resources

Kate has 20 years of experience working in People and Culture roles across health, finance and professional services. She is passionate about supporting people to be their best at work and executes this through building strong relationships, understanding and alternative perspectives.

Bindhu Radhakrishnan

Bindhu Radhakrishnan

Director of Quality

Bindhu leads our QA, QC and Validation teams, with overall responsibility for the QMS and GMP compliance at Cell Therapies. She has over 20 years of experience in the pharma industry and is a passionate supporter of embedding Quality and Continuous improvement.

Our Advisory Team

Dominic Wall

Associate Professor Dominic Wall

Founder and Strategic Advisor

As co-founder of Cell Therapies and former Chief Scientific Officer, Dominic serves as a strategic advisor, leveraging deep industry expertise in the manufacture and delivery of innovative cell-based therapies for clinical trials and commercial supply. Dominic also holds an appointment at the Peter MacCallum Cancer Centre as Executive Director-Business Ventures, overseeing the Centre of Excellence in Cellular Immunotherapy, Theranostics, and Pathology.

Our Board of Directors

Michelle Burke

Michelle Burke

Chair, Director

Deirdre experience includes Chief Operating Officer at Arts Centre Melbourne where her responsibilities include Finance, IT and digital, Facilities Management, Strategic Planning, Risk Management and more. Deirdre was on the Peter MacCallum Cancer Centre Board until July 2032, and is Chair of the Audit and Risk Management Committee.

Deidre Blythe

Deidre Blythe

Director

Deirdre experience includes Chief Operating Officer at Arts Centre Melbourne where her responsibilities include Finance, IT and digital, Facilities Management, Strategic Planning, Risk Management and more. Deirdre was on the Peter MacCallum Cancer Centre Board until July 2032, and is Chair of the Audit and Risk Management Committee.

svg+xml;charset=utf

Libby Secomb

Director

With over 20 years’ experience, Libby is a Finance professional with a demonstrated history of working in the financial services industry. She is skilled in operational leadership, Financial Risk, Internal Audit, Risk Management, and Corporate Finance. Before her successful career as a finance and accounting professional, Libby was a medical laboratory scientist at the Royal Children’s Hospital.

Matt OKeefe

Matt O’Keefe

Director

Matt O’Keefe is a Board Director of the Peter MacCallum Cancer Centre and the Chairman of the Finance Committee. With more than 25 years’ technology, finance and assurance experience, he specialises in technology advisory and offers numerous services across technology governance and risk, project management, and more.

AusBiotech
BioMelbourne Network
VCCC
Melbourne Biomedical Precinct
Peter Mac
ISCT
Royal Melbourne Hospital

Our Partners, Memberships and Associations

Ecosystem Engagement To Drive Sector Growth

Cell Therapies supports the growth of the Australian and Asia-Pacific cell and gene therapy sector through partnerships and collaborations with biotech companies, pharmaceutical companies, healthcare, industry, and government.

Our commitment to GMP manufacturing excellence of complex cell and gene therapies underpins our Purpose and Values.

Collaborate with us

Unrivalled experience and service from a global leader in cell and gene therapy manufacturing

To reach out to our expert team, enter your details and we will arrange a call at a time that suits you.

svg+xml;charset=utf

cell therapies is an Australian-based, globally-active commercial contract development and manufacturing company, specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products

Services
Helpful Links
Corporate

Victorian Comprehensive Cancer Centre
Level 9, 305 Grattan Street,
Melbourne, VIC,3000
Australia

+61 3 9492 4777
[email protected]

Copyright 2025 © Cell Therapies Pty Ltd – All rights reserved.

Secret Link